Company intelligence / Profile preview

MIG USA

High Point, North Carolina, United Statessekisuiseikei.co.jp ↗

Ownership: Private
Development stage: Other

Overview

MIG USA rapidly launched and distributed the VITAK‑19 rapid-result COVID antibody test kit during the early phase of the pandemic. The kit detects IgG/IgM antibodies from a fingertip blood sample with results in about eight minutes. It was positioned as an accessible, point-of-care or self-administered diagnostic solution to address urgent testing needs[1].

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic device
Industry: Protein Biomarker Diagnostics

Partnerships

Unnamed corporate partner for manufacturing/distribution rights to VITAK‑19 test kit[1]

Beyond the preview

Go deeper on MIG USA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIG USA.

Explore the full profile